RE:RE:RE:Napkin mathHere is my napkin scratching; The Netherlands is a unique model where each clinic is solely focused on skincancer screening. The numbers there are not representative of a normal channel partner.The Netherlands is number 5 in the world for skin cancer and the programme in the Netherlands is sponsored by the Government. If MedX does 20 patients a day and recieves $10 per scan on 312 days a year that equates to $62,000 per clinic. They plan to expand to 41 clinics in 2 years according to the press release so ~$2.5 million once every clinic is installed of recurring revenue. So this is great progress but you cannot base their rollout on these numbers,this is a unique market in my opinion.
I think a reasonable number per install would be 2 scans a day per location X 312 days x $10 x number of installs.$6,240 per location of recurring revenue x 1500 as in your example would = $9,360,000 of annual recurring revenue. The stockmarket pays 10-12 X's for this kind of revenue so that equates to almost 100 million market capitalization.
These are the numbers extrapolated from the Beacon research and I think MedX is well funded and needs to execute to show shareholders that the Netherlands was not a one off transaction but they have meny more in their salespipeline.
Hope this helps